BRF1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09372(BRF1 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09372(BRF1 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

BRF1 (B-related factor 1), also known as TFIIB-related factor 1 or BRF2. is a transcription factor critical for RNA polymerase III (Pol III)-mediated transcription. It forms part of the TFIIIB complex, which binds to promoters of small non-coding RNAs, including tRNA, 5S rRNA, and other regulatory RNAs essential for cellular functions like translation and RNA processing. Structurally, BRF1 contains a TFIIB-like core domain and zinc ribbon motifs that facilitate interactions with Pol III and promoter DNA. Dysregulation of BRF1 has been implicated in cancers, neurodegenerative diseases, and viral infections due to its role in controlling cell growth and stress responses.

Antibodies targeting BRF1 are widely used to study its expression, localization, and molecular interactions in both normal and pathological contexts. They are applied in techniques such as Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). Commercially available BRF1 antibodies are typically raised in hosts like rabbits or mice, with monoclonal and polyclonal variants offering different specificity profiles. Validation often includes knockout cell lines or siRNA-mediated silencing to confirm target recognition. Researchers also use these antibodies to explore BRF1's role in oncogenesis, particularly in cancers with elevated Pol III activity, and its potential as a therapeutic target. Quality control for BRF1 antibodies emphasizes minimal cross-reactivity with related proteins, such as BRF2 or TFIIB.